NCT04766021View on ClinicalTrials.gov

Mirabegron and Physiological Function in Cold Environments

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

April 27, 2023

Study Completion Date

April 27, 2023

Conditions
Resting Energy ExpenditureThermogenesisBrown Adipose Tissue
Interventions
DRUG

Mirabegron

Dose-response effect on thermogenesis

DRUG

Placebo

Placebo control condition

Trial Locations (1)

47405

Indiana University, Bloomington

All Listed Sponsors
collaborator

Office of Naval Research (ONR)

FED

lead

Indiana University

OTHER

NCT04766021 - Mirabegron and Physiological Function in Cold Environments | Biotech Hunter | Biotech Hunter